A5032001510- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Viral-associated cancers and disorders
- Glioma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Silicon Carbide Semiconductor Technologies
- Lung Cancer Treatments and Mutations
- Protein Degradation and Inhibitors
- Eosinophilic Disorders and Syndromes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Advancements in Semiconductor Devices and Circuit Design
- Venous Thromboembolism Diagnosis and Management
- Autoimmune and Inflammatory Disorders Research
- Monoclonal and Polyclonal Antibodies Research
- IgG4-Related and Inflammatory Diseases
Mayo Clinic in Florida
2018-2025
WinnMed
2015-2024
Jacksonville College
2018-2024
King Faisal Specialist Hospital & Research Centre
2022
Mayo Clinic in Arizona
2013-2022
Creative Commons
2022
Mayo Clinic Hospital
2020-2022
Klinikum Oldenburg
2021
Cairo University
2020
Universität Hamburg
2020
Abstract: Brentuximab vedotin (BV) and nivolumab are increasingly utilized as a novel regimen in patients with relapsed/refractory classical Hodgkin lymphoma (cHL). A 26-year-old male presented to the hospital refractory diabetic ketoacidosis multiple electrolyte abnormalities, 9 days after first dose of brentuximab for recurrent lymphoma. During his hospitalization, he developed multi-organ failure. His workup showed elevated cytokine levels concerning severe release syndrome (CRS)...
Majority of non-Hodgkin lymphoma (NHL) patients who achieve partial response (PR) or stable disease (SD) to CAR T-cell therapy (CAR T) on day +30 progress and only 30% spontaneous complete (CR). This study is the first evaluate role consolidative radiotherapy (cRT) for residual fluorodeoxyglucose (FDG) activity post- T in NHL. We retrospectively reviewed 61 with NHL received achieved PR SD +30. Progression-free survival (PFS), overall (OS), local relapse-free (LRFS) were assessed from...
Preclinical studies have shown augmented activity when combining Bruton tyrosine kinase inhibitors (BTKi) with of mammalian target rapamycin (mTOR) and immunomodulatory agents (IMiD). We conducted a phase 1, open-label study at five centers in USA to evaluate the safety triplet BTKi/mTOR/IMiD therapy. Eligible patients were adults aged 18 years or older relapsed/refractory CLL, B cell NHL, Hodgkin lymphoma. Our dose escalation used an accelerated titration design moved sequentially from...
7006 Background: Rituximab maintenance (RM) after first-line (1L) bendamustine and rituximab (BR) in MCL did not improve progression-free survival the MAINTAIN trial (Rummel et al, ASCO 2016) but was associated with improved outcomes a North American observational study (Martin JCO 2023). We sought to examine potential benefit of RM BR using large cohort from 26 US academic centers. Methods: Patients who received 1L (without stem cell transplant) outside clinical trials were included. At...
Multiple myeloma (MM) treatment has advanced significantly over the last 2 decades. In most patients, disease course been altered from early fatality to chronic morbidity with multiple lines of treatment. The MM paradigm shifted toward treating patients before end-organ damage occurs. Thus, timeliness initiation in this era might improve patient outcomes. This is first report our knowledge analyzing disparities and trends using National Cancer Database. factors affected timing were found. We...
Intravascular lymphoma (IVL) is a rare extranodal non-Hodgkin lymphoma. We performed retrospective analysis of 55 IVL patients who were treated at our institution 2003-2018. Median age diagnosis was 68 years, and 64% males. The most frequent presenting symptoms skin rash 43% weight loss 30%. MRI brain on with CNS involvement (CNS-IVL) showed multifocal in 76% (13/17). 89% (17/19) non-CNS-IVL abnormal FDG-PET had biopsy an avid lesion resulting definitive diagnosis. top diagnostic site the...
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well age-related macular degeneration eye. It vascular endothelial growth factor inhibitor which exhibits its action by blocking blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, increased risk infections. Atypical hemolytic uremic syndrome serious effect...
Stent migration is an uncommon complication of endovascular stenting procedures. It could cause serious cardiovascular complications. In this article, we describe interesting case acute heart failure as a result stent embolization from the left common iliac vein into right ventricle and how it was identified managed.
This study compares reduced (<27 Gy) to standard dose (≥30 radiation therapy (RT) in the treatment of gastric extranodal marginal zone lymphoma mucosa-associated lymphoid tissue (gMALT lymphoma).Forty-two patients with stage I or II disease were retrospectively reviewed. Response RT was assessed endoscopy after RT. Complete response rate (CR), freedom from failure, and overall survival (OS) calculated.All (n = 40) 2). All had residual biopsy proven gMALT before Twenty-six (61.9%) treated RT,...
Frosted branch angiitis (FBA) is a rare form of retinal vasculitis with typical perivascular edema taking the shape frost on tree branch. It was reported only twice as initial presentation Hodgkin lymphoma (HL). Here, we present first case paraneoplastic FBA sign HL relapse in an elderly female.
Summary Ruxolitinib for steroid‐refractory acute graft‐ versus ‐host disease (SR‐aGVHD) results in resistance or intolerance 1/5 of patients. Outcomes such patients are undefined. We identified these a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was 48/307 Among receiving additional therapy, the overall response rate to next therapy 36%. Median survival 21 days. led treatment discontinuation 16/307 Ten intolerant received with 50% experiencing continued improvement...
IntroductionYttrium-90 ibritumomab tiuxetan [(90)Y-IT] is a CD20-targeted radio-immuno conjugate. Clinical trials of (90)Y-IT as first-line stand-alone treatment in follicular lymphoma (FL) and/or marginal zone (MZL) showed high efficacy. However, long-term survival outcomes and toxicities are not well-defined.MethodsWe report retrospective single-institution, multi-center study previously untreated low grade (LG)-FL MZL at Mayo Clinic Cancer Center between January 2000 October 2019. We...
Cutaneous paraneoplastic syndromes due to Hodgkin lymphoma present with a wide spectrum of clinical manifestations from generalized pruritus exfoliative erythroderma. We summarize the findings and outcomes 14 patients associated cutaneous treated at Mayo Clinic over past 3 decades. may be time diagnosis, whereas in other patients, it appear relapse, including initial absence during presentation. Our results indicate that complete resolution syndrome is significantly improved overall...